Literature DB >> 23068101

MYBPH inhibits NM IIA assembly via direct interaction with NMHC IIA and reduces cell motility.

Yasuyuki Hosono1, Jiro Usukura, Tomoya Yamaguchi, Kiyoshi Yanagisawa, Motoshi Suzuki, Takashi Takahashi.   

Abstract

Actomyosin filament assembly is a critical step in tumor cell migration. We previously found that myosin binding protein H (MYBPH) is directly transactivated by the TTF-1 lineage-survival oncogene in lung adenocarcinomas and inhibits phosphorylation of the myosin regulatory light chain (RLC) of non-muscle myosin IIA (NM IIA) via direct interaction with Rho kinase 1 (ROCK1). Here, we report that MYBPH also directly interacts with an additional molecule, non-muscle myosin heavy chain IIA (NMHC IIA), which was found to occur between MYBPH and the rod portion of NMHC IIA. MYBPH inhibited NMHC IIA assembly and reduced cell motility. Conversely, siMYBPH-induced increased motility was partially, yet significantly, suppressed by blebbistatin, a non-muscle myosin II inhibitor, while more profound effects were attained by combined treatment with siROCK1 and blebbistatin. Electron microscopy observations showed well-ordered paracrystals of NMHC IIA reflecting an assembled state, which were significantly less frequently observed in the presence of MYBPH. Furthermore, an in vitro sedimentation assay showed that a greater amount of NMHC IIA was in an unassembled state in the presence of MYBPH. Interestingly, treatment with a ROCK inhibitor that impairs transition of NM IIA from an assembly-incompetent to assembly-competent state reduced the interaction between MYBPH and NMHC IIA, suggesting that MYBPH has higher affinity to assembly-competent NM IIA. These results suggest that MYBPH inhibits RLC and NMHC IIA, independent components of NM IIA, and negatively regulates actomyosin organization at 2 distinct steps, resulting in firm inhibition of NM IIA assembly.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23068101     DOI: 10.1016/j.bbrc.2012.10.036

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Experimental Modeling Supports a Role for MyBP-HL as a Novel Myofilament Component in Arrhythmia and Dilated Cardiomyopathy.

Authors:  David Y Barefield; Megan J Puckelwartz; Ellis Y Kim; Lisa D Wilsbacher; Andy H Vo; Emily A Waters; Judy U Earley; Michele Hadhazy; Lisa Dellefave-Castillo; Lorenzo L Pesce; Elizabeth M McNally
Journal:  Circulation       Date:  2017-08-04       Impact factor: 29.690

Review 2.  The heavy chain has its day: regulation of myosin-II assembly.

Authors:  Natalya G Dulyaninova; Anne R Bresnick
Journal:  Bioarchitecture       Date:  2013 Jul-Aug

3.  Genome-wide identification of AR-regulated genes translated in Sertoli cells in vivo using the RiboTag approach.

Authors:  Karel De Gendt; Guido Verhoeven; Paul S Amieux; Miles F Wilkinson
Journal:  Mol Endocrinol       Date:  2014-02-25

Review 4.  MYH9: Structure, functions and role of non-muscle myosin IIA in human disease.

Authors:  Alessandro Pecci; Xuefei Ma; Anna Savoia; Robert S Adelstein
Journal:  Gene       Date:  2018-04-19       Impact factor: 3.688

Review 5.  Myosin Heavy Chain 9: Oncogene or Tumor Suppressor Gene?

Authors:  Yunmei Wang; Shuguang Liu; Yanjun Zhang; Jin Yang
Journal:  Med Sci Monit       Date:  2019-01-31

6.  MYH9 Promotes Growth and Metastasis via Activation of MAPK/AKT Signaling in Colorectal Cancer.

Authors:  Bin Wang; Xiaolong Qi; Jian Liu; Rui Zhou; Chuang Lin; Junjie Shangguan; Zhuoli Zhang; Liang Zhao; Guoxin Li
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

7.  MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer.

Authors:  Longyang Liu; Juanjuan Yi; Xiaojie Deng; Jianhuan Yuan; Beixian Zhou; Zhongqiu Lin; Zhaoyang Zeng
Journal:  Oncol Lett       Date:  2019-05-27       Impact factor: 2.967

8.  High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors.

Authors:  Tyler J W Robinson; Melody Pai; Jeff C Liu; Frederick Vizeacoumar; Thomas Sun; Sean E Egan; Alessandro Datti; Jing Huang; Eldad Zacksenhaus
Journal:  Cell Cycle       Date:  2013-08-12       Impact factor: 4.534

Review 9.  Life without double-headed non-muscle myosin II motor proteins.

Authors:  Venkaiah Betapudi
Journal:  Front Chem       Date:  2014-07-07       Impact factor: 5.221

Review 10.  Myosins as fundamental components during tumorigenesis: diverse and indispensable.

Authors:  Yan-Ruide Li; Wan-Xi Yang
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.